Verrica Pharmaceuticals reports Q3 adjusted EPS 13c, consensus (84c)

Reports Q3 revenue $14.34M, consensus $9.75M. “In the third quarter, Verrica achieved multiple commercial, corporate, scientific and regulatory milestones providing a strong foundation for future growth in YCANTH as well as significant upside potential from our late-stage clinical pipeline,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Throughout the past year, while growing adoption of YCANTH for molluscum, we have also significantly advanced our late-stage clinical programs in two of the highest unmet needs in dermatology.”